Multipronged T-Cell Receptor for Multi-Antigen Cancer Recognition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are limited in their ability to target multiple cancer antigens simultaneously, making it difficult to effectively combat the multifaceted nature of cancer, as conventional T-cells typically recognize a single cancer peptide through a specific T-cell receptor, limiting their effectiveness against diverse cancer types.
Innovation Solution
Development of 'multipronged T-cells' that utilize a single T-cell receptor to recognize and attack multiple distinct cancer peptides presented by the same human leukocyte antigen (HLA) class I molecule, along with anti-cancer peptides and vectors that prime the production of these T-cells, enhancing their ability to target various cancer types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional T-cells recognize a single cancer peptide through a specific T-cell receptor, then the T-cell can specifically target that peptide, but the T-cell cannot effectively combat multiple distinct cancer antigens simultaneously
Solution Approach 1:
The patent applies universality by designing a T-cell receptor that can recognize multiple distinct cancer peptides through a single receptor entity. The TCR is engineered to bind to different peptide-HLA complexes, enabling one T-cell to perform multiple targeting functions against various cancer antigens simultaneously, thus resolving the contradiction between versatility and reliability
2Reliability
If cancer cells present multiple distinct peptides, then the cancer is more effectively targeted, but the T-cell system becomes more complex to coordinate multiple antigens
Solution Approach 1:
The patent merges multiple antigen recognition capabilities into a single T-cell receptor entity. Instead of requiring separate T-cells for each cancer antigen, the invention combines multiple recognition specificities within one TCR, thereby reducing the complexity of coordinating multiple antigens while maintaining reliable effectiveness against diverse cancer types
Data Source
Figure 1A~1B
Figure 1C
Figure 2A
AI summary
The present disclosure relates to a new anti-cancer peptide; a vector encoding same; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said anti-cancer peptide; use of said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine to treat cancer; a method of treating cancer using said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine; and a combination therapeutic for the treatment of cancer comprising said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine.